Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA

European-Funded Research Project Seeks Molecular Basis for Chronic Pain

By BiotechDaily International staff writers
Posted on 26 Nov 2013
A consortium of research institutions and medical centers will be participating in a four-year program funded by the European commission that aims at exploring and defining molecular mechanisms underlying chronic pain.

One out of five Europeans suffers from chronic pain, a syndrome that can induce anxiety and depression and greatly impair the quality of life. It has been estimated that treatment of chronic pain costs the European national health systems up 1.5%–3% of their gross domestic product (GDP) each year.

The recently announced six million euro "ncRNAPain" project will be a cooperative effort of 11 universities, medical centers, and research institutes in seven countries (Austria, the Czech Republic, Denmark, France, Germany, Israel, and the United Kingdom.

The researchers, including those at the Hebrew University of Jerusalem (Israel), will focus on pain-regulating noncoding ribonucleic acids (ncRNAs). They will be seeking to identify and validate specific ncRNAs that could serve as basis for the development of new drugs for pain prevention and relief.

Dr. Hermona Soreq, professor of molecular neuroscience at The Hebrew University of Jerusalem, said, “MicroRNAs (a form of ncRNAs) are a new finding. They are only known for less than 20 years, but it is already clear that they have an important surveillance job, controlling many genes. They do that by wrapping around gene products, the RNA, and reducing their option to get translated into proteins. Furthermore, they block an entire series of genes, all involved in a pathway, so they work like general dimmers of electricity, so to speak, not blackening out but shadowing. We know about many hundreds of microRNAs, and a large part of those are unique to humans (so mouse tests will not be useful).”

“The new group is about microRNAs involved in pain—an important phenomenon which is often regarded as a symptom, whereas it should be taken more seriously as a phenomenon on its own merit and treated as such. This is especially the case in advanced ages, which also implies that its impact will increase with life expectancy prolongation,” said Dr. Soreq. “What we want to do is to combine sequencing tests in human blood cells with efforts to block excess microRNAs. There are many partners involved, including pain clinician specialists, but also basic researchers. We hope to gain new diagnostic biomarkers and find new targets for therapeutic interference.”

Related Links:

The Hebrew University of Jerusalem



Channels

Biochemistry

view channel
Image:  Model depiction of a novel cellular mechanism by which regulation of cryptochromes Cry1 and Cry2 enables coordination of a protective transcriptional response to DNA damage caused by genotoxic stress (Photo courtesy of the journal eLife, March 2015, Papp SJ, Huber AL, et al.).

Two Proteins Critical for Circadian Cycles Protect Cells from Mutations

Scientists have discovered that two proteins critical for maintaining healthy day-night cycles also have an unexpected role in DNA repair and protecting cells against genetic mutations that could lead... Read more

Business

view channel

NanoString and MD Anderson Collaborate on Development of Novel Multi-Omic Expression Profiling Assays for Cancer

The University of Texas MD Anderson Cancer Center (Houston, TX, USA) and NanoString Technologies, Inc. (Seattle, WA, USA) will partner on development of a revolutionary new type of assay—simultaneously profiling gene and protein expression, initially aiming to discover and validate biomarker signatures for immuno-oncology... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.